Key Highlights
- Paul A. LaViolette appointed Co-Chairman of Pulse Biosciences’ Board of Directors.
- LaViolette brings extensive experience in scaling global cardiology franchises.
- Current Managing Partner at SV Health Investors and former COO at Boston Scientific.
Source: Business Wire
Notable Quotes
- “We are thrilled to have Paul join the Pulse Biosciences Board. His track record speaks for itself as he has been influential in the medical technology space for decades.” – Robert W. Duggan, Co-Chairman at Pulse Biosciences
- “I am honored to join the Board at Pulse Biosciences. The Company’s highly differentiated and proprietary technology represents a truly unique opportunity.” – Paul A. LaViolette, Co-Chairman at Pulse Biosciences
SoHC's Take
The addition of Paul A. LaViolette to Pulse Biosciences’ Board of Directors is a strategic move that signals the company’s commitment to scaling its innovative technology within the medical field. LaViolette’s extensive background in both large-scale operations and venture investment within the healthcare sector provides Pulse Biosciences with invaluable leadership and insight. His proven track record at industry giants like Boston Scientific, combined with his advisory roles across numerous medical technology companies, positions Pulse Biosciences to effectively leverage its proprietary nsPFA™ technology in the evolving landscape of bioelectric medicine. This appointment is likely to bolster investor confidence and drive the company’s growth trajectory as it seeks to redefine clinical care standards.
